Transarterial chemoembolization (TACE) is a minimally invasive procedure that delivers chemotherapy directly into the blood vessels feeding a liver tumor while simultaneously blocking those vessels to starve the tumor of oxygen and nutrients. It’s the recommended treatment for intermediate-stage liver cancer that can’t be surgically removed, and it works by combining two cancer-fighting strategies: a high local dose of chemotherapy and deliberate disruption of the tumor’s blood supply.
How TACE Works
The liver has a unique blood supply. Normal liver tissue gets most of its blood from the portal vein, while liver tumors depend almost entirely on the hepatic artery. TACE exploits this difference. By targeting the hepatic artery branches that feed the tumor, doctors can deliver a concentrated dose of chemotherapy right to the cancer cells while cutting off their blood flow. The surrounding healthy liver tissue, still nourished by the portal vein, is largely spared.
During the procedure, a thin catheter is threaded through either the wrist or groin artery, guided up through the body’s arterial system, and positioned in the specific hepatic artery branch supplying the tumor. Doctors watch this process in real time using fluoroscopy, a type of live X-ray imaging. Once the catheter tip is in place, a mixture of chemotherapy and embolization particles is injected until blood flow to the tumor stalls completely. The result is a one-two punch: the chemotherapy kills cancer cells directly, and the blocked artery prevents the drug from washing away while depriving the tumor of the oxygen it needs to survive.
Two Main Types of TACE
Conventional TACE (cTACE) mixes a chemotherapy drug with an oily substance called Lipiodol, which acts as a carrier to shuttle the drug into the tumor’s tiny blood vessels. The mixture is prepared right before injection by pumping the two solutions back and forth through connected syringes at least 20 times to create a stable blend. After injection, additional particles (often made from gelatin sponge) may be used to further block the artery.
Drug-eluting bead TACE (DEB-TACE) uses tiny, uniform microspheres that are pre-loaded with chemotherapy. These beads physically block the feeding vessels while slowly releasing the drug over time, creating a sustained high concentration within the tumor. Because the drug release is more controlled, DEB-TACE tends to produce lower levels of chemotherapy circulating through the rest of the body. Studies comparing the two approaches show similar survival outcomes and treatment response rates, but DEB-TACE generally causes fewer side effects, particularly less liver toxicity and fewer systemic reactions. For patients with more advanced disease, DEB-TACE may offer a slight edge in tumor response. Both European and Asian clinical guidelines now list DEB-TACE as an acceptable alternative to conventional TACE.
Who Is a Candidate
TACE is the standard treatment for patients with Barcelona Clinic Liver Cancer (BCLC) intermediate-stage disease, often called stage B. These patients typically have multiple tumor nodules in the liver, are in good overall physical condition, and have reasonably preserved liver function (classified as Child-Pugh A or B). Crucially, they don’t have cancer that has spread outside the liver or invaded major blood vessels.
Certain conditions rule out TACE. Patients with significantly impaired liver function, including jaundice, severe fluid buildup in the abdomen, or liver-related brain dysfunction, are not candidates. Kidney problems, complete blockage of the portal vein, or significant abnormal connections between the hepatic artery and portal vein also disqualify patients. The procedure depends on the liver’s healthy tissue being able to sustain itself through the portal vein, so when liver function is too compromised, the risks outweigh the benefits.
What to Expect During the Procedure
TACE is performed by an interventional radiologist, typically under conscious sedation rather than general anesthesia. You’ll be awake but comfortable. The doctor numbs a small area at your wrist or groin, then inserts a needle to access the artery. A thin catheter is guided through the arterial system into the liver, and a smaller microcatheter is threaded into the precise artery feeding the tumor. The goal is to be as selective as possible, targeting only the tumor’s blood supply while leaving healthy tissue alone.
The entire process usually takes one to two hours. Once the chemotherapy and embolic material are delivered, the catheter is removed and the access site is closed with gentle pressure or a small closure device.
Recovery and Side Effects
Most people stay in the hospital for one to two nights after TACE. You can typically go home within 24 to 48 hours once pain and nausea are manageable with oral medications, and most people resume normal activities within about a week.
The most common aftereffect is post-embolization syndrome, which happens in the majority of patients. It feels like a combination of abdominal pain, low-grade fever, nausea, vomiting, and general fatigue. Pain tends to be worst in the first two to three hours, stays fairly constant for about 12 hours, then gradually eases. Fever and nausea typically peak around two to three days after the procedure. Fatigue and loss of appetite are slower to resolve and may linger for two weeks or longer. While unpleasant, post-embolization syndrome is an expected response to the treatment, not a complication.
How Effective Is TACE
TACE has been shown to improve survival compared to supportive care alone in patients with unresectable liver cancer. Median overall survival varies depending on how advanced the disease is at the time of treatment and how well the liver is functioning, but studies report figures in the range of 12 to 13 months in populations with mixed disease severity. In one study of 94 patients, about 18% achieved a complete response (no visible tumor on imaging) and another 20% had a partial response, for a combined objective response rate of roughly 38%.
TACE is often repeated. Because it rarely eliminates the entire tumor in one session, patients commonly undergo multiple treatments spaced weeks or months apart. Over time, however, some tumors stop responding. When that happens, guidelines from the American Association for the Study of Liver Diseases and several Asian liver cancer organizations recommend transitioning to systemic therapy rather than continuing with additional TACE sessions.
TACE Compared to Radioembolization
A related procedure called transarterial radioembolization (TARE) uses the same catheter-based approach but delivers tiny radioactive beads instead of chemotherapy. Both treatments target the tumor’s arterial blood supply, but they differ in how they destroy cancer cells: TACE relies on chemotherapy plus blood supply blockage, while TARE uses internal radiation.
A meta-analysis comparing the two found that TARE produced a longer time to tumor progression than TACE, with a mean of 17.5 months versus 9.8 months. Overall survival was similar between the two approaches, though direct comparisons are limited by differences in study design. TARE is increasingly used as an alternative, particularly for patients with single tumors up to 8 cm that haven’t responded to initial treatment. Some guidelines now also combine TACE with systemic drugs like targeted therapies for patients who meet specific criteria, reflecting a broader trend toward multi-modal treatment strategies for liver cancer.